Financial News, Latest News
Breaking News - Novocure (NASDAQ: NVCR): FDA Approves Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer Novocure (NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1...